Lafutidine
Alternative Names: FRG 8813; loctidine; Protecadin; StogarLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Fujirebio
- Developer Boryung Pharmaceutical; Taiho Pharmaceutical
- Class Acetamides; Antiulcers; Cytoprotectives; Gastric antisecretories; Piperidines; Pyridines; Small molecules
- Mechanism of Action Histamine H2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastric ulcer; Gastritis; Peptic ulcer; Reflux oesophagitis
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Peptic-ulcer in South Korea (PO, Tablet)
- 30 Nov 2015 Boryung completes phase I clinical trials for Peptic ulcer in South Korea (PO) (NCT02581696)
- 01 Oct 2015 Phase-I clinical trials in Peptic ulcer in South Korea (PO) (NCT02581696)